Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS). The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations (MCOs), including health fairs, on-site and at-home testing, vaccinations, and health screenings. In addition, the company offers online and mobile applications that enable patients to check test results; online applications for providers, MCOs, and accountable care organizations; and drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development, as well as support for crop protection and chemical testing. It serves pharmaceutical, biotechnology, medical device, and diagnostics companies; and MCOs, employer plans, other health insurance providers, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, independent clinical laboratories, and retailers. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
van der Vaart Sandra D | EVP, Chief Legal Officer | May 14 '24 | Sale | 210.83 | 2,000 | 421,655 | 5,637 | May 16 08:02 AM | ANDERSON KERRII B | Director | May 02 '24 | Sale | 200.10 | 250 | 50,025 | 15,722 | May 02 04:29 PM | ANDERSON KERRII B | Director | Apr 30 '24 | Sale | 204.13 | 250 | 51,034 | 15,972 | May 02 04:29 PM | Wilkinson Peter J | SVP, Chief Accounting Officer | Apr 29 '24 | Sale | 204.33 | 2,439 | 498,358 | 2,087 | May 01 06:29 PM | Schroeder Mark S | EVP, Pres Diagnostics & COO | Apr 01 '24 | Sale | 217.29 | 6,477 | 1,407,387 | 5,036 | Apr 03 08:35 AM | Summy Amy B. | EVP, Chief Marketing Officer | Apr 01 '24 | Sale | 217.29 | 3,500 | 760,515 | 3,975 | Apr 03 08:34 AM | van der Vaart Sandra D | EVP, Chief Legal Officer | Mar 28 '24 | Sale | 216.74 | 3,553 | 770,077 | 7,637 | Mar 29 05:54 PM | Schroeder Mark S | EVP, Pres Diagnostics & COO | Mar 07 '24 | Option Exercise | 117.09 | 2,119 | 248,114 | 10,084 | Mar 11 08:59 AM | Schroeder Mark S | EVP, Pres Diagnostics & COO | Mar 07 '24 | Sale | 218.45 | 5,048 | 1,102,736 | 5,036 | Mar 11 08:59 AM | Summy Amy B. | EVP, Chief Marketing Officer | Mar 07 '24 | Sale | 218.45 | 227 | 49,588 | 3,859 | Mar 11 08:56 AM | EISENBERG GLENN A | Chief Financial Officer, EVP | Feb 21 '24 | Option Exercise | 163.63 | 14,054 | 2,299,656 | 58,099 | Feb 22 03:05 PM | EISENBERG GLENN A | Chief Financial Officer, EVP | Feb 21 '24 | Sale | 215.97 | 34,504 | 7,451,866 | 23,595 | Feb 22 03:05 PM | DiVincenzo Jonathan P. | EVP, Pres, Central Labs & Intl | Feb 21 '24 | Sale | 215.49 | 500 | 107,745 | 3,401 | Feb 22 03:04 PM | van der Vaart Sandra D | EVP, Chief Legal Officer | Feb 13 '24 | Sale | 226.45 | 237 | 53,669 | 7,637 | Feb 15 08:32 AM | van der Vaart Sandra D | EVP, Chief Legal Officer | Feb 08 '24 | Sale | 222.06 | 259 | 57,514 | 7,637 | Feb 09 12:19 PM | van der Vaart Sandra D | EVP, Chief Legal Officer | Feb 05 '24 | Sale | 220.57 | 193 | 42,570 | 7,637 | Feb 06 03:47 PM | Wilkinson Peter J | SVP, Chief Accounting Officer | Nov 16 '23 | Sale | 210.71 | 1,384 | 291,627 | 2,087 | Nov 20 12:23 PM | ANDERSON KERRII B | Director | Aug 08 '23 | Sale | 211.57 | 5,000 | 1,057,832 | 15,275 | Aug 10 08:55 AM | van der Vaart Sandra D | EVP, Chief Legal Officer | Jun 29 '23 | Sale | 240.00 | 212 | 50,880 | 7,605 | Jul 03 11:52 AM | Kirchgraber Paul R | CEO, Covance Drug Development | May 19 '23 | Option Exercise | 182.51 | 4,300 | 784,793 | 17,246 | May 23 08:06 AM | Kirchgraber Paul R | CEO, Covance Drug Development | May 19 '23 | Sale | 216.91 | 4,300 | 932,707 | 12,946 | May 23 08:06 AM |
|